Sinobiomed Announces New Chief Executive Officer

Sinobiomed Announces New Chief Executive Officer
New, Experienced Management Intends to Move Swiftly on Funding, Acquisitions and Corporate Initiatives 

HONG KONG, Sep 2, 2010 (GlobeNewswire via COMTEX) -- The Board of Directors of Sinobiomed Inc. ("Sinobiomed", or "the Company") (Pink Sheets:SOBM) is pleased to announce the appointment of a new Chief Executive Officer.

George Yu, incoming President and Chief Executive Officer, has over 15 years of management and corporate development experience. Mr. Yu had worked in operational management roles in technology start-ups in the late 1990s and later acted as management consultant to Fortune 500 companies at Bain. His corporate finance experience includes working at small-cap hedge and venture capital funds in emerging markets and investment banking at Lehman Brothers. Mr. Yu graduated from Columbia Business School magna cum laude in Finance and Economics.

Mr. Yu plans to implement immediately the following strategic initiatives:


  --  Identify strategic acquisition and investment opportunities in
      high-growth industries
  --  Build a results-oriented management team
  --  Execute strategic transactions intended to accelerate the growth of the
      company and create significant shareholder value
  --  Obtain necessary funding to execute strategic transactions
  --  Focus on operational excellence to deliver results

 

 


FORWARD LOOKING STATEMENTS: This news release may include "forward-looking statements" regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Sinobiomed, Inc.

CONTACT:  Sinobiomed Inc.
Investor Relations
Intl.
+86 136 0191 6614
U.S.
+1 415 830 6210
[email protected]
Room 4304, 43/F China Resources Building
26 Harbour Road
Wan Chai
Hong Kong

 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.